Metabolic effect of two hormonal preparations in postmenopausal women

Maturitas

Volumn 27, Issue 3, 1997, Pages 275-284

  Bissonnette, François ^a,d   Lussier Cacan, Suzanne ^b   Fugère, Pierre ^a   Bérubé, Sophie ^c  

^a UNIVERSITY OF MONTREAL   (Canada)

^b CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^c INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^d NONE   (Canada)

Author keywords

Hormone replacement therapy; Metabolic effect; Postmenopause

Indexed keywords

ANGIOTENSIN; BLOOD CLOTTING FACTOR; CONJUGATED ESTROGEN; CYPROTERONE ACETATE; CYPROTERONE ACETATE PLUS ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRONE; FOLLITROPIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIOTHYRONINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; MEDROXYPROGESTERONE ACETATE; PRASTERONE; SEX HORMONE; THYROTROPIN;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; HORMONAL REGULATION; HORMONE DEFICIENCY; HUMAN; HUMAN EXPERIMENT; LIPID METABOLISM; LUTEINIZING HORMONE BLOOD LEVEL; POSTMENOPAUSE; STATISTICAL ANALYSIS; TESTOSTERONE BLOOD LEVEL; THYROTROPIN BLOOD LEVEL;

EID: 0030739530     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(97)00042-X     Document Type: Article

References (27)

1. Kanell WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease. The Framingham Study. Ann Intern Med 1976;85:447-52.
2. Jensen J, Riis BJ, Christiansen C. Cyproterone acetate, an alternative progestogen in postmenopausal hormone replacement therapy? Effects on serum lipids and lipoproteins. Br J Obset Gynaecol 1987;94:136-41.
3. Rijpkema AHM, van der Sanden AA, Ruijs AHC. Effects of post-menopausal oestrogen-progestogen replacement therapy on serum lipids and lipoproteins: a review. Maturitas 1990;12:259-85.
4. Colditz GA, Stampfer MJ, Cardiovascular effects of menopause and estrogen replacement: The epidemiological evidence. In: Swartz DP, editor. Hormonal Replacement Therapy. Baltimore: Williams and Wilkins, 1992:109-138.
5. Whitehead MI, King RJB, McQueen J, Campbell S. Endometrial histology and biochemistry in climacteric women during estrogen and oestrogen/pregestogen therapy. J R Soc Med 1979;72:322-7.
6. Hirvonen E, Mälkönen M, Manninen V. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy. N Engl J Med 1981;304:560-3.
7. Schneider HPG, Schmidt-Gollwitzer K, Clinical experiences with non-androgenic progestogen in an estradiol-valerate-containing regimen for hormone replacement therapy. In: Schneider HPG, Genazzani AR, editors. New developments in Biosciences 7: A new approach to the treatment of climacteric disorders. Berlin-New York: Walter de Gruyter, 1992:18-28.
8. Mashchak CA, Lobo RA, Dozono-Takano R, Eggena P, Nakamura RM, et al. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obset Gynecol 1982;144:511-29.
9. Neuman F. The physiological action of progesterone and the pharmacological effects of progestogens-a short review. Postgrad Med J 1978;54:11-24.
10. Lussier-Cacan S, Dubreuil-Quidoz S, Roederer G, Leboeuf N, Boulet L, et al. Influence of Probucol on enhanced LDL oxidation after fish oil treatment of hypertriglyceridemic patients. Arthrioscler Thromb 1993;13:1790-7.
11. Campagnoli C, Lesca L, Cantamessa C, Peris C. Long-term hormone replacement treatment in menopause: new choices, old apprehensions, recent findings. Maturitas 1993;18:21-46.
12. Harlap S. The benefits and risks of hormone replacement therapy: An epidemiologic overview. Am J Obstet Gynecol 1992;166:1986-92.
13. Hassager C, Riis BJ, Strøm V, Guyene TT, Christiansen C. The long-term effect of oral and percutaneous estradiol on plasma renin substrate and blood pressure. Circulation 1987;76:753-8.
14. van Wersch JWJ, Ubachs JMH, van den Ende A, van Enk A. The effect of two regimens of hormone replacement therapy on the haemostatic profile in post-menopausal women. Eur J Clin Chem Biochem 1994;6:449-53.
15. Volpe A, Facchinetti F, Grasso A, Petraglia F, Campanin D, et al. Benefits and risks of different hormonal replacement therapies in post-menopausal women. Maturitas 1986;8:327-34.
16. Crook D, Stevenson JC, Whitehead MI, Estrogen replacement therapy and cardiovasular disease: Effects on plasma lipid risk markers. In: Swartz DP, editor. Hormonal Replacement Therapy. Baltimore: Williams and Wilkins, 1992:139-169.
17. Metka M, Hanes V, Heytmanek G. Hormone replacement therapy: lipid responses to continuous combined oestrogen and progestogen versus oestrogen monotherapy. Maturitas 1992;15:53-9.
18. Tikkanen MJ, Combination of estradiol valerate and cyproterone acetate-a modern regimen for hormone replacement therapy. In: Schneider HPG, Genazzani AR, editors. New development in Biosciences 7: A new approach to the treatment of climacteric disorders. Berlin-New York: Walter de Gruyter, 1992:9-15.
19. Jensen J, Riis BJ, Strøm V, Christiansen C. Long-term and withdrawal effects of two different oestrogen-progestogen combinations on lipid and lipoprotein profiles in post-menopausal women. Maturitas 1989;11:117-28.
20. Sherwin BB, Gelfand MM. A prospective one-year study of estrogen and progestin in postmenopausal women: Effects on clinical symptoms and lipoprotein lipids. Obset Gynecol 1989;73:759-66.
21. Lobo RA, Pickar JH, Wild RA, Walsh B, Hirvonen E. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obset Gynecol 1994;84:987-95.
22. The Writing Group for the PEPI trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995;273:199-208.
23. Miller VT, Muesing RA, LaRosa JC, Stoy DB, Fowler SA, et al. Quantitative and qualitative changes in lipids, lipoproteins, apolipoproteins A-I, and sex hormone-binding globulin due to two doses of conjugates equine estrogen with and without a progestin. Obset Gynecol 1994;83:173-9.
24. Tikkanen MJ, Kuusi EA, Nikkilä E, Sipinen S. Post-menopausal hormone replacement therapy: effects of progestogens on serum lipids and lipoproteins. A review. Maturitas 1986;8:7-17.
25. Bottiglioni F, de Aloysio D, Nicoletti G, Mauloni M, Mantuana R, et al. A study of thyroid function in the pre-and post-memopause. Maturitas 1983;5:105-14.
26. Chetkowski RJ, Meldrum DR, Steingold KA, Randle D, Lu JK, et al. Biologic effects of transdermal estradiol. N Engl J Med 1986;314:1615-20.
27. Saleh AA, Dorey LG, Dombrowski MP, Ginsburg KA, Hirokawa S, et al. Thombosis and hormonal replacement therapy in postmenopausal women. Am J Obset Gynecol 1993;169:1554-7.